Says at the bottom "The company paid consideration to SNN or its affiliates for this article". If this were news it should be done in a press release.
This "article" says that "The trial will be conducted in the U.S. and Europe by premiere oncology CRO, Translational Drug Development (TD2). I thought they said that they have broken away from TD2 as their CRO???